IL298794B2 - History of triazines with virus replication inhibitory activity and a pharmaceutical preparation containing them - Google Patents
History of triazines with virus replication inhibitory activity and a pharmaceutical preparation containing themInfo
- Publication number
- IL298794B2 IL298794B2 IL298794A IL29879422A IL298794B2 IL 298794 B2 IL298794 B2 IL 298794B2 IL 298794 A IL298794 A IL 298794A IL 29879422 A IL29879422 A IL 29879422A IL 298794 B2 IL298794 B2 IL 298794B2
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- same
- inhibitory activity
- virus replication
- triazine derivatives
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003918 triazines Chemical class 0.000 title 1
- 230000029812 viral genome replication Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021068672 | 2021-04-14 | ||
JP2021105802 | 2021-06-25 | ||
JP2021153819 | 2021-09-22 | ||
PCT/JP2022/006496 WO2022138988A1 (ja) | 2021-04-14 | 2022-02-17 | ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
IL298794A IL298794A (en) | 2023-02-01 |
IL298794B1 IL298794B1 (en) | 2024-02-01 |
IL298794B2 true IL298794B2 (en) | 2024-06-01 |
Family
ID=82159864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL298794A IL298794B2 (en) | 2021-04-14 | 2022-02-17 | History of triazines with virus replication inhibitory activity and a pharmaceutical preparation containing them |
Country Status (14)
Country | Link |
---|---|
US (2) | US20230128162A1 (es) |
EP (1) | EP4122926A4 (es) |
JP (2) | JP7105430B1 (es) |
KR (2) | KR20230159812A (es) |
CN (4) | CN115073431B (es) |
AU (1) | AU2022204775B2 (es) |
CA (1) | CA3195272C (es) |
CL (1) | CL2023003041A1 (es) |
CO (1) | CO2022016323A2 (es) |
IL (1) | IL298794B2 (es) |
MX (1) | MX2022014458A (es) |
TW (1) | TWI815396B (es) |
WO (2) | WO2022138988A1 (es) |
ZA (1) | ZA202212526B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022138988A1 (ja) * | 2021-04-14 | 2022-06-30 | 塩野義製薬株式会社 | ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物 |
WO2023033098A1 (ja) * | 2021-09-03 | 2023-03-09 | 塩野義製薬株式会社 | ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物 |
TW202320793A (zh) * | 2021-09-28 | 2023-06-01 | 日商塩野義製藥股份有限公司 | 含有三嗪衍生物之醫藥組合物 |
CN116782904A (zh) * | 2021-09-28 | 2023-09-19 | 盐野义制药株式会社 | 含有三嗪衍生物的医药组合物 |
JP7236065B1 (ja) * | 2021-09-28 | 2023-03-09 | 塩野義製薬株式会社 | トリアジン誘導体を含有する医薬組成物 |
EP4289432A1 (en) * | 2021-11-24 | 2023-12-13 | Shionogi & Co., Ltd | Preparation for oral administration containing triazine derivative |
JP7261529B1 (ja) | 2021-11-24 | 2023-04-20 | 塩野義製薬株式会社 | ウイルス増殖阻害作用を有するトリアジン誘導体の製造方法 |
WO2023095860A1 (ja) * | 2021-11-26 | 2023-06-01 | 塩野義製薬株式会社 | 3clプロテアーゼ阻害剤及びcovid-19治療用薬剤を組み合わせることを特徴とするcovid-19治療用医薬 |
JP7273455B1 (ja) * | 2022-01-19 | 2023-05-15 | 塩野義製薬株式会社 | 新型コロナウイルス感染症治療用医薬 |
WO2023165459A1 (en) * | 2022-03-01 | 2023-09-07 | Fochon Biosciences , Ltd. | Compounds as sars-cov-2 inhibitors |
US11655240B1 (en) * | 2022-05-10 | 2023-05-23 | Beijing Grand Johamu Pharmaceutical Company, Ltd. | Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases |
CN114805314B (zh) * | 2022-04-20 | 2023-12-15 | 杭州国瑞生物科技有限公司 | 一种恩赛特韦的合成方法 |
WO2023227118A1 (zh) * | 2022-05-27 | 2023-11-30 | 广州国家实验室 | 3c样蛋白酶抑制剂 |
CN117122601A (zh) * | 2022-05-27 | 2023-11-28 | 北京远大九和药业有限公司 | 包含化合物与富马酸的结晶形式的药物组合物及其制备方法和用途 |
WO2023226679A1 (zh) * | 2022-05-27 | 2023-11-30 | 广州国家实验室 | 3c样蛋白酶抑制剂 |
CN117159555A (zh) * | 2022-05-27 | 2023-12-05 | 北京远大九和药业有限公司 | 药物组合物及其制备方法和用途 |
WO2023227117A1 (zh) * | 2022-05-27 | 2023-11-30 | 广州国家实验室 | 3c样蛋白酶抑制剂 |
CN115260167A (zh) * | 2022-08-01 | 2022-11-01 | 陕西盘龙药业集团股份有限公司 | 一种3-四唑基甲基-1,3,5-三嗪-2,4-二酮类化合物及其制备方法和应用 |
CN115490681B (zh) * | 2022-07-08 | 2023-04-18 | 歌礼生物科技(杭州)有限公司 | 三嗪衍生物 |
WO2024009120A1 (en) * | 2022-07-08 | 2024-01-11 | Ascletis Bioscience Co., Ltd. | Triazine derivatives and methods of use thereof |
CN114989048B (zh) * | 2022-07-19 | 2023-05-23 | 郑州大学 | 环丁-1-烯胺类化合物及其制备方法和在抗ⅱ型登革病毒药物中的应用 |
CN114933594A (zh) * | 2022-07-20 | 2022-08-23 | 北京科翔中升医药科技有限公司 | 一种氟代三嗪类化合物、药物组合物及用途 |
CN115109042B (zh) * | 2022-08-30 | 2023-05-26 | 北京科翔中升医药科技有限公司 | 三嗪类化合物或其可药用的盐、药物组合物和用途 |
CN116514783A (zh) * | 2022-11-21 | 2023-08-01 | 歌礼生物科技(杭州)有限公司 | 三嗪衍生物 |
CN115819407A (zh) * | 2022-12-13 | 2023-03-21 | 浙江乐普药业股份有限公司 | 一种Ensitrelvir类似物及其制备方法和抗新冠用途 |
CN115785080A (zh) * | 2022-12-16 | 2023-03-14 | 陕西盘龙药业集团股份有限公司 | 一种尿嘧啶母核类化合物及其制备方法和应用 |
CN116621817B (zh) * | 2023-07-20 | 2023-09-29 | 爱斯特(成都)生物制药股份有限公司 | 一种富马酸恩赛特韦的晶型及其制备方法、药物组合物和用途 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2383954T3 (es) * | 2000-01-25 | 2012-06-27 | Neurocrine Biosciences, Inc | Antagonistas del receptor de la hormona liberadora de ganodotropina y métodos relacionados con ellos |
CN102134229B (zh) * | 2004-03-15 | 2020-08-04 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
CN1926128A (zh) * | 2004-03-15 | 2007-03-07 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
WO2006104715A1 (en) * | 2005-03-24 | 2006-10-05 | Janssen Pharmaceutica, N.V. | Prokineticin 1 receptor antagonists |
CN102675221A (zh) * | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | 用于制备嘧啶二酮衍生物的方法中的中间体 |
CN100502868C (zh) * | 2005-11-18 | 2009-06-24 | 北京大学 | 非肽类sars冠状病毒3cl蛋白酶抑制剂及其用途 |
CN101495464B (zh) * | 2005-12-29 | 2014-03-05 | 詹森药业有限公司 | 激肽原1受体拮抗剂 |
WO2007112368A1 (en) * | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Preparation of (r)-3-aminopiperidine dihydrochloride |
ES2525716T3 (es) * | 2007-06-27 | 2014-12-29 | Astrazeneca Ab | Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares |
JP2011502154A (ja) * | 2007-10-30 | 2011-01-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | アミノヘテロアリールを含むプロキネチシン1受容体拮抗物質連邦政府支援研究又は開発に関する陳述下に記述される本発明の研究及び開発は、連邦政府の支援によるものではない。 |
MX2011008362A (es) | 2009-02-13 | 2011-08-24 | Shionogi & Co | Derivado novedoso de triazina y composicion farmaceutica que comprende el mismo. |
WO2012006004A1 (en) * | 2010-06-28 | 2012-01-12 | Janssen Pharmaceutica Nv | Prokineticin 1 receptor antagonists for the treatment of pain |
WO2012006003A1 (en) * | 2010-06-28 | 2012-01-12 | Janssen Pharmaceutica Nv | Prokineticin 1 receptor antagonists for the treatment of pain |
WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
JP6075621B2 (ja) | 2010-08-10 | 2017-02-08 | 塩野義製薬株式会社 | 新規複素環誘導体およびそれらを含有する医薬組成物 |
CA2807947C (en) * | 2010-08-10 | 2018-06-19 | Shionogi & Co., Ltd. | Triazine derivative and pharmaceutical compound that contains same and exhibits analgesic activity |
CN102807568B (zh) * | 2011-05-31 | 2015-11-25 | 正大天晴药业集团股份有限公司 | 噻二唑衍生物类dpp-iv抑制剂 |
CN103159665B (zh) * | 2011-12-09 | 2017-01-25 | 天津市国际生物医药联合研究院 | 对sars冠状病毒主蛋白酶具有抑制作用的靛红‑5‑酰胺类抑制剂 |
WO2013089212A1 (ja) | 2011-12-15 | 2013-06-20 | 塩野義製薬株式会社 | 置換トリアジン誘導体およびそれらを含有する医薬組成物 |
US9550763B2 (en) | 2012-02-09 | 2017-01-24 | Shionogi & Co., Ltd. | Heterocyclic ring and carbocyclic derivative |
TWI637949B (zh) | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
JP6403172B2 (ja) * | 2013-10-25 | 2018-10-10 | シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドShanghai Hengrui Pharmaceutical Co., Ltd. | ピリジンのケトン誘導体、それらの製造方法、およびそれらの医薬適用 |
CN104109147B (zh) * | 2014-06-21 | 2016-10-05 | 安徽省逸欣铭医药科技有限公司 | 羟基脒基苯类衍生物及其制备方法和医药用途 |
JP7116356B2 (ja) * | 2017-11-28 | 2022-08-10 | 日産化学株式会社 | トリアジン-2,4-ジオン誘導体及びその製造方法 |
CN114641485A (zh) | 2020-04-05 | 2022-06-17 | 辉瑞大药厂 | 用于治疗covid-19的化合物和方法 |
CN112516122A (zh) * | 2020-04-21 | 2021-03-19 | 洪楠方 | 苏拉明在制备预防或治疗冠状病毒相关疾病药物中的用途 |
WO2022035911A2 (en) * | 2020-08-11 | 2022-02-17 | Tutela Pharmaceuticals, Inc. | Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent |
US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
EP4282420A1 (en) * | 2021-01-20 | 2023-11-29 | National University Corporation Hokkaido University | Anti-viral agent |
WO2022138988A1 (ja) * | 2021-04-14 | 2022-06-30 | 塩野義製薬株式会社 | ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物 |
CN113801097B (zh) | 2021-09-27 | 2022-11-22 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物、其制备方法及用途 |
CN113666914B (zh) | 2021-09-27 | 2022-06-07 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物及其制备方法和用途 |
CN113735838B (zh) | 2021-09-27 | 2022-07-08 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物、其制备方法及用途 |
CN113620888B (zh) | 2021-09-27 | 2023-06-06 | 成都施贝康生物医药科技有限公司 | 二氢嘧啶类化合物及其制备方法和应用 |
CN113773300B (zh) | 2021-09-27 | 2022-10-11 | 成都施贝康生物医药科技有限公司 | 磺酰胺类化合物、其制备方法及用途 |
CN116782904A (zh) * | 2021-09-28 | 2023-09-19 | 盐野义制药株式会社 | 含有三嗪衍生物的医药组合物 |
TW202320793A (zh) * | 2021-09-28 | 2023-06-01 | 日商塩野義製藥股份有限公司 | 含有三嗪衍生物之醫藥組合物 |
EP4289432A1 (en) * | 2021-11-24 | 2023-12-13 | Shionogi & Co., Ltd | Preparation for oral administration containing triazine derivative |
JP7273455B1 (ja) * | 2022-01-19 | 2023-05-15 | 塩野義製薬株式会社 | 新型コロナウイルス感染症治療用医薬 |
CN117069706A (zh) * | 2022-05-10 | 2023-11-17 | 北京远大九和药业有限公司 | 一种化合物的结晶形式及其制备方法和用途 |
-
2022
- 2022-02-17 WO PCT/JP2022/006496 patent/WO2022138988A1/ja active Application Filing
- 2022-02-17 EP EP22733282.2A patent/EP4122926A4/en active Pending
- 2022-02-17 CN CN202210742186.2A patent/CN115073431B/zh active Active
- 2022-02-17 KR KR1020237002784A patent/KR20230159812A/ko unknown
- 2022-02-17 WO PCT/JP2022/006495 patent/WO2022138987A1/ja unknown
- 2022-02-17 US US17/790,358 patent/US20230128162A1/en active Pending
- 2022-02-17 IL IL298794A patent/IL298794B2/en unknown
- 2022-02-17 JP JP2022525557A patent/JP7105430B1/ja active Active
- 2022-02-17 CN CN202310437344.8A patent/CN116650498A/zh active Pending
- 2022-02-17 KR KR1020227018680A patent/KR102494188B1/ko active IP Right Grant
- 2022-02-17 CA CA3195272A patent/CA3195272C/en active Active
- 2022-02-17 CN CN202311797713.0A patent/CN117820248A/zh active Pending
- 2022-02-17 JP JP2022571730A patent/JPWO2022138987A1/ja active Pending
- 2022-02-17 MX MX2022014458A patent/MX2022014458A/es unknown
- 2022-02-17 AU AU2022204775A patent/AU2022204775B2/en active Active
- 2022-02-17 CN CN202280000918.9A patent/CN115038696A/zh active Pending
- 2022-04-13 TW TW111113943A patent/TWI815396B/zh active
- 2022-04-29 US US17/733,366 patent/US11814368B2/en active Active
- 2022-11-15 CO CONC2022/0016323A patent/CO2022016323A2/es unknown
- 2022-11-16 ZA ZA2022/12526A patent/ZA202212526B/en unknown
-
2023
- 2023-10-11 CL CL2023003041A patent/CL2023003041A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20230128162A1 (en) | 2023-04-27 |
IL298794A (en) | 2023-02-01 |
CA3195272C (en) | 2024-02-13 |
CN116650498A (zh) | 2023-08-29 |
US20230212154A1 (en) | 2023-07-06 |
CA3195272A1 (en) | 2022-06-30 |
CL2023003041A1 (es) | 2024-03-15 |
EP4122926A1 (en) | 2023-01-25 |
JPWO2022138988A1 (es) | 2022-06-30 |
CN115073431B (zh) | 2023-09-05 |
JP7105430B1 (ja) | 2022-07-25 |
WO2022138988A1 (ja) | 2022-06-30 |
IL298794B1 (en) | 2024-02-01 |
CN117820248A (zh) | 2024-04-05 |
TWI815396B (zh) | 2023-09-11 |
CN115850249A (zh) | 2023-03-28 |
CN115073431A (zh) | 2022-09-20 |
KR102494188B1 (ko) | 2023-01-31 |
US11814368B2 (en) | 2023-11-14 |
WO2022138987A1 (ja) | 2022-06-30 |
MX2022014458A (es) | 2023-02-27 |
AU2022204775B2 (en) | 2023-03-30 |
EP4122926A4 (en) | 2023-08-30 |
CN115038696A (zh) | 2022-09-09 |
AU2022204775A1 (en) | 2022-12-08 |
KR20220142999A (ko) | 2022-10-24 |
JPWO2022138987A1 (es) | 2022-06-30 |
KR20230159812A (ko) | 2023-11-22 |
TW202302571A (zh) | 2023-01-16 |
CO2022016323A2 (es) | 2023-02-16 |
ZA202212526B (en) | 2023-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL298794B2 (en) | History of triazines with virus replication inhibitory activity and a pharmaceutical preparation containing them | |
IL289925A (en) | Consequences of adenosine and a pharmaceutical preparation containing it | |
EP3481831A4 (en) | NOVEL 4-AMINOPYRAZOLO [3,4-D] PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
BR112016008016A2 (pt) | inibidores de kras g12c | |
EP3929195A4 (en) | NEW PYRIDO[3,4-D]PYRIMIDIN-8-ONE DERIVATIVE HAVING PROTEIN KINASE INHIBITOR ACTIVITY, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, RELIEVING OR TREATING CANCER, INCLUDING THE SAME | |
EP3810601A4 (en) | PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF CANCER THEREOF | |
EP3412292B8 (en) | Use of methoxatin, derivative and/or salt thereof in sjogren's syndrome and pharmaceutical composition | |
WO2016126085A3 (ko) | 헤테로 고리 화합물 및 그를 포함하는 약제학적 조성물 | |
EP3999183A4 (en) | COMPOUND EXHIBITING KDM5 INHIBITORY ACTIVITY AND ASSOCIATED PHARMACEUTICAL USE | |
RS63401B1 (sr) | Derivati 2,4-diaminohinazolina i njihova upotreba u lečenju virusnih infekcija, kancera ili alergija | |
EP4092029A4 (en) | 7-AMINO-3,4-DIHYDROPYRIMIDOPYRIMIDIN-2-ONE DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST PROTEIN KINASES AND THERAPEUTIC PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | |
EP3858353A4 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING NITM AND ASSOCIATED PHARMACEUTICAL USE | |
EP4041734C0 (en) | DERIVATIVES CONTAINING 1,2,3,4-TETRAHYDRONAPHTHALENE UNIT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
IL284930A (en) | History of pyrrolopyrimidines and their use in the treatment of protein kinase-related diseases | |
IL279702A (en) | Pyridine and pyridazine derivatives are converted in positions 3 and 5 and their pharmaceutical uses | |
IL288645A (en) | Conjugated saponin and vaccine or a pharmaceutical composition containing it | |
IL291388A (en) | Heterocyclic derivatives, pharmaceutical preparations and their use for the treatment or alleviation of cancer | |
WO2017188720A3 (en) | Quinazoline derivative or its salt and pharmaceutical composition comprising the same | |
MX2020011200A (es) | Compuestos heteroaromaticos que tienen actividad contra vrs. | |
EP3750537A4 (en) | PHARMACEUTICAL COMPOSITION, EXCIPIENT FOR THE COMPOSITION AND USE OF THE COMPOSITION | |
IL304366A (en) | Consequences of adenosine and a pharmaceutical preparation containing it | |
GB2590189B (en) | Lycorine derivative, and pharmaceutical composition and use thereof | |
MX2021014301A (es) | Otros compuestos heteroaromaticos que tienen actividad contra el vrs. | |
EP4038064C0 (en) | N-SUBSTITUTED-6-OXO-1,6-DIHYDROPYRIMIDINE-2-YL DERIVATIVES AS HUMAN IMMUNODEFICIENCY VIRUS REPLICATION INHIBITORS | |
EP3778576A4 (en) | 2-CYANOPYRIMIDINE-4-YLCARBAMATE OR UREA DERIVATIVE OR SALT THEREOF AND PHARMACEUTICAL COMPOSITION THEREOF |